Differences in pharmacology and their translation into differences in clinical efficacy - A comparison of the renin angiotensin blocking agents irbesartan and losartan

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 4, 2010, Pages 521-535

  Bramlage, Peter ^a   Schindler, Christoph ^b  

^a Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Atrial fibrillation; Blood pressure; Diabetes; Heart failure; Irbesartan; Left ventricular hypertrophy; Losartan; Nephropathy; Stroke; Uric acid

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; AMLODIPINE; CANDESARTAN; DITHIOTHREITOL; DRUG METABOLITE; EPROSARTAN; EXP 3179; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; PIOGLITAZONE; PLACEBO; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; BACKACHE; BLOOD PRESSURE REGULATION; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMMON COLD SYMPTOM; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DENMARK; DIABETIC NEPHROPATHY; DISTRIBUTION VOLUME; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FATIGUE; FOOD DRUG INTERACTION; GERMANY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; MONOTHERAPY; MUSCULOSKELETAL PAIN; NONHUMAN; PHARMACODYNAMICS; POTASSIUM BLOOD LEVEL; QUALITY ADJUSTED LIFE YEAR; RENAL PROTECTION; REVIEW; SIDE EFFECT; SORE THROAT; SWEDEN; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; HEALTH CARE COSTS; HUMANS; HYPERTENSION; LOSARTAN; TETRAZOLES; TREATMENT OUTCOME;

EID: 77249107973     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903512962     Document Type: Review

References (53)

1. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
2. Stolk P, Van Wijk BL, Leufkens HG, et al. Between-country variation in the utilization of antihypertensive agents: guidelines and clinical practice. J Hum Hypertens 2006;20:917-22
3. Cazaubon C, Gougat J, Bousquet F, et al. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993;265:826-34
4. Delisee C, Schaeffer P, Cazaubon C, et al. Characterization of cardiac angiotensin AT1 receptors by [3H]SR 47436. Eur J Pharmacol 1993;247:139-44
5. Mazzolai L, Maillard M, Rossat J, et al. Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. Hypertension 1999;33:850-5
6. Belz GG, Butzer R, Kober S, et al. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. Clin Pharmacol Ther 1999;66:367-73
7. Nakashima M, Uematsu T, Kosuge K, et al. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992;42:333-5
8. Edwards RM, Trizna W, Stack EJ, et al. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. J Pharmacol Exp Ther 1996;276:125-9
9. Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens 2002;11:475-82
10. Wurzner G, Gerster JC, Chiolero A, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001;19:1855-60
11. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-7
12. Schupp M, Lee LD, Frost N, et al. Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension 2006;47:586-9
13. Kappert K, Tsuprykov O, Kaufmann J, et al. Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPAR{gamma} Activation. Hypertension 2009;54:738-43
14. Kassler-Taub K, Littlejohn T, Elliott W, et al.; Irbesartan/Losartan Study Investigators. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Am J Hypertens 1998;11:445-53
15. Oparil S, Guthrie R, Lewin AJ, et al.; Irbesartan/Losartan Study Investigators. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Clin Ther 1998;20:398-409
16. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3:283-91
17. Sheiner LB, Beal SL, Sambol NC. Study designs for dose-ranging. Clin Pharmacol Ther 1989;46:63-77
18. Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press 2002;11:293-301
19. Sharplin P. An analysis of the antihypertensive effectiveness of irbesartan vs. losartan across both single and in combination with HCTZ formulations. J Hypertens 2008;26:S169-70
20. Petrella RJ, Massien C. What is the effectiveness of ARBs versus other anti-hypertensives when used as monotherapy in the real-world? ISPOR 2009:PCV23
21. Neutel JM, Smith D. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/ hydrochlorothiazide and losartan/ hydrochlorothiazide in patients with mild-to-moderate hypertension. J Int Med Res 2005;33:620-31
22. Knudsen MS, Lange M, Dahl E. Cost effectiveness of long term treatment of hypertension with irbesartan vs. losartan or no treatment in Denmark. Value Health 2006;9:A348
23. Ekman M, Bienfait-Beuzon C, Jackson J. Cost-effectiveness of irbesartan/ hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden. J Hum Hypertens 2008;22:845-55
24. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
25. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
26. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
27. Agha A, Amer W, Anwar E, et al. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial. Saudi J Kidney Dis Transpl 2009;20:429-35
28. Ratzmann KP, Pirk O, Carels J, et al. Cost-saving potentials in the therapy of hypertonic type 2 diabetics due to delayed end-stage renal disease. Pharmacoeconomics German Res Articles 2004;2:43-52
29. Tonkon M, Awan N, Niazi I, et al; Irbesartan Heart Failure Group. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Int J Clin Pract 2000;54:11-6
30. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003;138:542-9
31. Kum LC, Yip GW, Lee PW, et al. Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure. Int J Cardiol 2008;125:16-21
32. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-67
33. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52
34. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7
35. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840-8
36. Hudson M, Humphries K, Tu JV, et al. Angiotensin II receptor blockers for the treatment of heart failure: a class effect? Pharmacotherapy 2007;27:526-34
37. Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens 1998;16(Suppl):S23-9
38. Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001;19:1167-76
39. Gaudio C, Ferri FM, Giovannini M, et al. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol 2003;42:622-8
40. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
41. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-6
42. Madrid AH, Marin IM, Cervantes CE, et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004;5:114-20
43. Dagres N, Karatasakis G, Panou F, et al. Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation. Eur Heart J 2006;27:2062-8
44. O'Riordan M. Irbesartan in atrial fibrillation: no overall benefit, but it may prevent later heart failure. 2009. Available from: http://www.theheart. org/article/ 998137.do [Last accessed 26 November 2009]
45. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-19
46. Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:705-11
47. Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006;47:46-50
48. Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006;27:1841-6
49. Lan X, Su L, Ling Z, et al. Catheter ablation vs. amiodarone plus losartan for prevention of atrial fibrillation recurrence in patients with paroxysmal atrial fibrillation. Eur J Clin Invest 2009;39:657-63
50. Saygili E, Rana OR, Saygili E, et al. Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes. Am J Physiol Heart Circ Physiol 2007;292:H2898-905
51. Nomura M, Kawano T, Nakayasu K, et al. The effects of losartan on signal-averaged P wave in patients with atrial fibrillation. Int J Cardiol 2008;126:21-7
52. Schindler C, Ferrario CM. Olmesartan for the treatment of arterial hypertension. Future Cardiol 2008;4:357-72
53. Kirch W, Horn B, Schweizer J. Comparison of angiotensin II receptor antagonists. Eur J Clin Invest 2001;31:698-706